Header Logo

Connection

MICHAEL R MIGDEN to Aged

Back to Details
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Aged.
MICHAEL R MIGDEN
Connection Strength
0.393
Aged
  1. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol. 2023 Jun 01; 33(3):280-286.
    View in: PubMed
    Score: 0.036
  2. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.032
  3. Multiple inguinal basal cell carcinomas in the setting of intertrigo. Indian J Dermatol Venereol Leprol. 2020 Jul-Aug; 86(4):469.
    View in: PubMed
    Score: 0.029
  4. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305.
    View in: PubMed
    Score: 0.028
  5. Mohs Micrographic Surgery for the Treatment of Cutaneous Metastases in a Patient With Papillary Thyroid Carcinoma. Dermatol Surg. 2018 11; 44(11):1457-1459.
    View in: PubMed
    Score: 0.026
  6. A Tender Subcutaneous Fluctuant Forehead Nodule: An Unexpected Foray Into the Cranium. Dermatol Surg. 2018 Sep; 44(9):1224-1227.
    View in: PubMed
    Score: 0.026
  7. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
    View in: PubMed
    Score: 0.025
  8. Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol. 2018 Sep; 79(3):520-524.
    View in: PubMed
    Score: 0.025
  9. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017 Jul; 77(1):55-62.e3.
    View in: PubMed
    Score: 0.023
  10. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
    View in: PubMed
    Score: 0.021
  11. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35(2):221-228.
    View in: PubMed
    Score: 0.009
  12. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
    View in: PubMed
    Score: 0.008
  13. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.008
  14. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.008
  15. Varicella-zoster virus detection by polymerase chain reaction using bronchoalveolar lavage specimens. Am J Respir Crit Care Med. 2000 Aug; 162(2 Pt 1):753-4.
    View in: PubMed
    Score: 0.007
  16. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.007
  17. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.007
  18. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol. 2019 Feb; 46(2):152-158.
    View in: PubMed
    Score: 0.007
  19. Venous Treatment of Lipodermatosclerosis to Improve Ambulatory Function. Dermatol Surg. 2018 May; 44(5):749-752.
    View in: PubMed
    Score: 0.006
  20. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
    View in: PubMed
    Score: 0.006
  21. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
    View in: PubMed
    Score: 0.006
  22. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
    View in: PubMed
    Score: 0.006
  23. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120.
    View in: PubMed
    Score: 0.006
  24. Phototherapeutic keratectomy for corneal scars. Ophthalmic Surg Lasers. 1996 May; 27(5 Suppl):S503-7.
    View in: PubMed
    Score: 0.005
  25. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
    View in: PubMed
    Score: 0.005
  26. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
    View in: PubMed
    Score: 0.005
  27. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.
    View in: PubMed
    Score: 0.005
  28. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003.
    View in: PubMed
    Score: 0.005
  29. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.